Download as PDF, PPTX
Uploaded byPrasad Bhat
Pharmacovigilance ppt
The document discusses pharmacovigilance, the science centered on monitoring and preventing adverse drug reactions to enhance patient safety and public health. It outlines the history of pharmacovigilance in India, the need for a functional system, and the importance of reporting adverse drug reactions. Additionally, it describes the reporting process and the periodic safety update reports that evaluate the risk-benefit balance of medications.
More Related Content
Similar to Pharmacovigilance ppt
Pharmacovigilance ppt
- 1.
- 2. Pharmacovigilance It is thepharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse reaction with Pharmaceutical products. "Pharmacovigilance” ( Pharmakon -drug +Vigilare to keep watch) Pharmacovigilance (PV) Drug Safety PHARMACOVIGILANCE
- 3. Aims & Scope •To improve patient care & safety in relation to medicines & all medical & para-medical interventions • To improve public health & safety in relation to the use of medicines Public Health • To contribute to the assessment of benefit, harm, effectiveness and risk of medicines Risk Benefit Assessment • To promote understanding, clinical training & effective communication to health professionals & the public Communication Patient Care PHARMACOVIGILANCE
- 4. Dying from adisease is sometimes unavoidable; but dying from a medicine is unacceptable.
- 5. Pharmacovigilance in India:A Brief History • • National Pharmacovigilance Programme •Pharmacovigilance Programme of India •India joined WHO-ADR monitoring programme (3 centers: AIIMS, KEM, • JLN) •ADR monitoring system for India proposed (12 regional centers) 1982 & 1989 1997 2004 – 2008 2010
- 6. Why do weneed pharmacovigilance? Humanitarian concern ADR May cause sudden death Promoting rational use of medicines and adherence Ethics To know of something that is harmful to another person who does not know, and not telling, is unethical PHARMACOVIGILANCE
- 7. Humanitarian concern –Insufficient evidence of safety from CLINICAL TRIALS ANIMAL EXPERIMENTS It has been suggested that ADRs may cause 5700 deaths per year in UK. Pirmohamed et al, 2004 ADRs were 4th-6th commonest cause of death in the US in 1994 Lazarou et al, 1998 ADRs are expensive !! 6.5% of admissions are due to ADRs Seven 800-bed hospitals are occupied by ADR patients Cost £446 million per annum PHARMACOVIGILANCE Why do we need pharmacovigilance?
- 8. The Minimum Requirementsfor a functional Pharmacovigilance System 1. A National Pharmacovigilance Centre with designated staff (at least one full time), stable basic funding, clear mandates, well defined structures and roles and collaborating with the WHO Programme for International Drug Monitoring. 2. The existence of a National spontaneous reporting system with a national individual case safety report (ICSR) form i.e. ADR reporting form PHARMACOVIGILANCE
- 9. 3. A nationaldatabase or system for collating and managing ADR reports 4. A national ADR or pharmacovigilance advisory committee able to provide technical assistance on causality assessment, risk assessment, risk management case investigation and where necessary crisis management including crisis communication 5.Clear communication strategy for routine communication and crises communication PHARMACOVIGILANCE
- 10. What information shouldbe reported ? PHARMACOVIGILANCE
- 11. ANY INFORMATION on anADR or lack of efficacy connected with the use of a medical device/ drug product. on ADRs occurring in the course of the use of a drug from drug overdose whether accidental or intentional from drug abuse / misuse / non-approved use from drug withdrawal in the infant of a nursing mother possibly as a result of exposure of the mother or the fetus during pregnancy. even if no ADR has been observed, From drug overdose whether accidental or intentional From drug abuse / misuse / non-approved use From drug administration during pregnancy. PHARMACOVIGILANCE
- 12.
- 13. PV Work Flow Datacollection (ICSR) Data entry in Data base Case processing (AMC) Review Panel (NCC) Causality Assessment Signal Detection Aggregate reporting (PSUR) Regulatory Authorities (CDSCO) Action UMC , Sweden
- 14.
- 15.
- 16. ADR Reporting throughvigiflow. VigiFlow is a web-based Individual Case Safety Report (ICSR) management system that is specially designed for use by national centres in the WHO Programme for International Drug Monitoring. VigiFlow 5.1(Released on 14 June 2013) Subscription for Vigiflow is free in India. Other tools: ARISg (mainly used by Drug manufacturer in Europe) Argus (mainly used by Drug manufacturer in USA) Vigibase PHARMACOVIGILANCE
- 17.
- 18.
- 19. As per ScheduleY, PSUR includes all safety reports - Spontaneous AE reports, PMS studies, Safety info from other sources - published articles etc. Subsequent to approval of the product, new drugs should be closely monitored for their clinical safety once they are marketed. The applicants shall furnish Periodic Safety Update Reports (PSURs) in order to - Report all the relevant new information from appropriate sources; Relate these data to patient exposure; Summarize the market authorization status in different countries and any significant variations related to safety; and Indicate whether changes should be made to product information in order to optimize the use of the product. Overview Of PSUR PHARMACOVIGILANCE
- 20. Aggregate Reporting (PSUR) •Key role in safety assessment of Drugs. • It involves compilation of safety data of drug over a prolonged period of time. Advantages: Provides broader view of safety profile of a drug. • PSUR Worldwide, the most important aggregate report is the Periodic Safety Update Report (PSUR). PHARMACOVIGILANCE
- 22. Periodic safety updatereports (PSURs) • (PSURs) now called as PBRER (Periodic benefit risk evaluation report, 21Jul2012) are Pharmacovigilance documents intended to provide an evaluation of the risk-benefit balance of a medicinal product for submission at defined time points during the post- authorisation phase. • The PSUR should focus on summary information, scientific safety assessment and integrated benefit-risk evaluation. PHARMACOVIGILANCE
- 23.
- 24. Submission frequency forPSURs • First 2 yrs: every 6 month • Next 2 yrs: every year • After that every 3 years. On the basis of PSURs: Regulatory Authorities take the appropriate decision for marketing of particular medicinal product. PHARMACOVIGILANCE
- 25.
- 26. ACPL provide servicesentails the generation of well‐structured individual reports supporting extensive medical writing programs, including: Aggregate report writing/ Medical and technical writing for PSURs Product Feasibility Reports for Medical Devices/Drugs Medical and technical writing for clinical study reports and annual reports Clinical Summaries. SAE Narratives for Clinical Study Reports RMP, SOP writing What We Do….. Pharmacovigilance / Safety / Medical Writing Services PHARMACOVIGILANCE
- 27. Recently banned drugsin India • Serodiagnostic test kits for diagnosis of tuberculosis (with effect from 7Jun2013). • Dextropropoxyphene (with effect from 23May2013) . • Fixed dose combination of Flupentixol+Melitracen (with effect from 18Jun2013). • Analgin (with effect from 18Jun2013) • Pioglitazone (with effect from 18Jun2013) PHARMACOVIGILANCE
- 28. THANK YOU ACCREDITED CONSULTANTSPVT. LTD. (Email: [email protected], [email protected], Website: acplgroupindia.co.in) (Contact: +91 22758204, 9350040434, 9310040434, Fax: 22758994) D-29, 1ST FLOOR, ACHARYA NIKETAN, MAYUR VIHAR PHASE-I, NEW DELHI-110091 PHARMACOVIGILANCE